{"id":"W4397049853","doi":"10.1016/j.clml.2024.05.014","title":"Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"Bristol-Myers Squibb","keywords":"Pomalidomide; Medicine; Nivolumab; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine; Lenalidomide; Materials science; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00172744,0.0008073832,0.00186756,0.0003905258,0.0002708946,0.00130406,0.0008280386,0.0007433702,0.002066975],"category_scores_gemma":[0.0009895486,0.0002823911,0.001797886,0.0005005708,0.0004632699,0.0007436958,0.0003824133,0.001936011,0.0004678716],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00131581,"about_ca_system_score_gemma":0.001227898,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002238005,"about_ca_topic_score_gemma":0.007218749,"domain_scores_codex":[0.9995378,0.0002112466,0.00002472293,0.00006905283,0.00008481655,0.00007244705],"domain_scores_gemma":[0.99942,0.0001309531,0.0001495343,0.00003953165,0.00003721007,0.0002227755],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6422228,0.0225469,0.01933881,0.001534869,0.007967639,0.000162926,0.0002461574,0.00433729,0.01724536,0.0005201079,0.01187609,0.2720011],"study_design_scores_gemma":[0.7505774,0.1269589,0.09592298,0.0002092151,0.005738684,0.0004873498,0.0001566285,0.002683383,0.002823219,0.0007159022,0.01363496,0.00009134607],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9821077,0.01045816,0.000302387,0.0006478041,0.000151245,0.0006439219,0.002183564,0.0001148047,0.003390307],"genre_scores_gemma":[0.9823178,0.006260203,0.001110579,0.002077361,0.000194974,0.0006306033,0.004910909,0.00006359829,0.002433942],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002238005,"threshold_uncertainty_score":0.009546995,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06850739743317062,"score_gpt":0.3881246018626424,"score_spread":0.3196172044294717,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}